The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question-are polyphenols a viable therapeutic option against proteinopathies?
Ann Transl Med. 2020 Jun;8(11):719.
doi: 10.21037/atm.2020.01.117.
1 Department of Neurology, David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California, Los Angeles, CA, USA.